TheStreet cut shares of Nektar Therapeutics (NASDAQ:NKTR) from a c rating to a d+ rating in a report published on Wednesday.

A number of other research analysts also recently weighed in on the company. ValuEngine upgraded Nektar Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 28th. Zacks Investment Research downgraded Nektar Therapeutics from a hold rating to a sell rating in a report on Monday, October 22nd. Cowen set a $86.00 target price on Nektar Therapeutics and gave the stock a buy rating in a report on Thursday. Piper Jaffray Companies set a $125.00 target price on Nektar Therapeutics and gave the stock a buy rating in a report on Wednesday, July 25th. Finally, HC Wainwright set a $54.00 target price on Nektar Therapeutics and gave the stock a hold rating in a report on Monday, October 22nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $79.55.

NKTR opened at $34.02 on Wednesday. The company has a market cap of $6.55 billion, a price-to-earnings ratio of -61.85 and a beta of 2.91. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55. Nektar Therapeutics has a one year low of $31.37 and a one year high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.07. The business had revenue of $27.80 million during the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a return on equity of 113.04% and a net margin of 59.71%. Nektar Therapeutics’s quarterly revenue was down 81.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.37 EPS. Equities research analysts forecast that Nektar Therapeutics will post 3.57 EPS for the current fiscal year.

In related news, Director R Scott Greer sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total value of $673,900.00. Following the sale, the director now owns 140,333 shares in the company, valued at approximately $9,457,040.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dennis L. Winger sold 34,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares in the company, valued at approximately $3,628,425. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock worth $5,825,680 in the last quarter. Company insiders own 4.31% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. FMR LLC grew its stake in shares of Nektar Therapeutics by 6.7% in the 2nd quarter. FMR LLC now owns 25,705,902 shares of the biopharmaceutical company’s stock worth $1,255,220,000 after buying an additional 1,608,834 shares during the last quarter. BlackRock Inc. grew its stake in shares of Nektar Therapeutics by 3.7% in the 3rd quarter. BlackRock Inc. now owns 13,121,756 shares of the biopharmaceutical company’s stock worth $799,902,000 after buying an additional 463,152 shares during the last quarter. OppenheimerFunds Inc. grew its stake in shares of Nektar Therapeutics by 7.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 11,560,779 shares of the biopharmaceutical company’s stock worth $564,512,000 after buying an additional 845,257 shares during the last quarter. First Trust Advisors LP grew its stake in shares of Nektar Therapeutics by 176.2% in the 3rd quarter. First Trust Advisors LP now owns 2,068,900 shares of the biopharmaceutical company’s stock worth $126,120,000 after buying an additional 1,319,776 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Nektar Therapeutics by 20.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,401,029 shares of the biopharmaceutical company’s stock worth $85,406,000 after buying an additional 241,111 shares during the last quarter. Institutional investors own 92.72% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Featured Story: Index Funds

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.